As a leader in global health, our top priority remains our customers, patients and employees. We are engaged in doing all that we can to help address this health crisis, including mobilising our best scientists to investigate diagnostics, new medicines and interventions for infection prevention.
On March 30, 2020, Johnson & Johnson announced that we have a lead vaccine candidate for COVID-19 in a landmark new partnership with the U.S. Department of Health & Human Services; and commitment to supply one billion vaccines worldwide for emergency pandemic use. And, together with Biomedical Advanced Research and Development Authority (BARDA), we have committed more than one billion dollars to Novel Coronavirus Vaccine Research and Development; and we expect to initiate phase 1 of human clinical studies of the vaccine candidate at latest by September 2020.
In January 2020, Johnson & Johnson announced our support of frontline health workers through our Johnson & Johnson Center for Health Worker Innovation, committing $250M over 10 years. On March 30, 2020, the Johnson & Johnson Family of Companies and the Johnson & Johnson Foundation announced they are increasing that commitment by $50M for immediate COVID-19 response, primarily focused on supporting frontline health workers. Now more than ever, we are applying all of our capabilities to the needs of nurses, doctors, midwives and community health workers. This fight is not new for us nor will it end in weeks; our support will respond to urgent, short-term needs while building a thriving health workforce for the long-term.
Johnson & Johnson is committed to helping individuals and communities around the world manage the unprecedented impacts of COVID-19. Learn more: here
Back to top